Retension Pharmaceuticals, Inc. went public at $12.00 a share
It sold 3,750,000 shares on Nasdaq Capital Market under the ticker RTSN and raised $45.0 million before costs.
Final prospectus (424B4) filed October 9, 2026
The terms
-
Offered
3,750,000 shares
Checked
Source
“We are offering 3,750,000 shares of common stock in this offering.”
A model read this, and code confirmed the quote appears in the filing. -
Price per share
$12.00
Checked
Source
“The initial public offering price for our common stock is $12.00 per share.”
A model read this, and code confirmed the quote appears in the filing. -
Raised
$45,000,000before fees and costs
Checked
Source and check
Shares × price = 3,750,000 × $12.00 = $45,000,000. They match.
“Initial public offering price | $12.00 | $45,000,000”
A model read this, and code confirmed the quote appears in the filing. -
Bank fee
$3,150,000$0.84 a share, 7.0% of the raise
Checked
Source
“Underwriting discounts and commissions(1) | $0.84 | $3,150,000”
A model read this, and code confirmed the quote appears in the filing. -
Company receives first
$41,850,000before other costs
Checked
Source and check
Raised − bank fee = $45,000,000 − $3,150,000 = $41,850,000. They match.
“Proceeds to us, before expenses | $11.16 | $41,850,000”
A model read this, and code confirmed the quote appears in the filing. -
Lead banks
Leerink Partners, Guggenheim Securities, Oppenheimer & Co.
From the prospectus
Source
“Leerink Partners | Guggenheim Securities | Oppenheimer & Co.”
A model read this, and code confirmed the quote appears in the filing. -
Trades as
RTSN on Nasdaq Capital Market
Checked
Source
“Our common stock is listed on the Nasdaq Capital Market (“Nasdaq”), under the symbol “RTSN.””
A model read this, and code confirmed the quote appears in the filing. -
Extra for the banks
Up to 562,500 sharesan option the banks may use
From the prospectus
Source
“We have granted the underwriters an option for a period of 30 days from the date of this prospectus to purchase up to 562,500 additional shares of common stock from us at the initial public offering price less the underwriting discounts and commissions.”
A model read this, and code confirmed the quote appears in the filing. - Final prospectus filed October 9, 2026
Not investment advice.Open the filing on SEC.gov
Where the money goes first
The banks take their fee before the company sees the money.
Who owns the company after the IPO
From the prospectus 3,750,000 of 8,331,599 shares outstanding after the offering (45.0%).
Where Retension Pharmaceuticals, Inc. sits among the last 12 months
Each bubble is one IPO. Bigger and higher means more money raised. The scale grows by ten times at each line.
New to these terms? How to read an IPO.